Daxxify and Dysport are both botulinum toxin type A injectables used to smooth dynamic wrinkles. They share the same mechanism — blocking acetylcholine release at the neuromuscular junction — but they differ in formulation, FDA-approved indications, onset speed, duration, diffusion behavior, and cost structure. The choice between them is not "which is better" but "which tradeoff matches the patient."
This comparison covers what the labels say, what clinical data support, and where the evidence is thin or marketing-driven.
What each product is
Daxxify (daxibotulinumtoxinA-lanm) is manufactured by Revance Therapeutics. It received FDA approval in September 2022 for the temporary improvement of moderate to severe glabellar lines in adults. In August 2023, it received an additional approval for cervical dystonia. The distinguishing feature is its excipient: RTP-004, a proprietary peptide that stabilizes the toxin molecule without human or animal serum components. Daxxify is the only marketed botulinum toxin A that contains no human serum albumin. It is also room-temperature stable, unlike Botox and Dysport, which require refrigeration.
Dysport (abobotulinumtoxinA) is manufactured by Ipsen and distributed in the U.S. by Galderma. It was first approved by the FDA in 2009 for glabellar lines, and has additional approvals for cervical dystonia, upper limb spasticity in adults, and lower limb spasticity in pediatric patients. Dysport uses human serum albumin as a stabilizer and requires refrigeration (2–8°C). Per the FDA prescribing information, the labeled dose for glabellar lines is 50 Units divided into five equal intramuscular injections of 10 Units each.
The active toxin (150 kDa botulinum toxin type A) is essentially the same molecule in both products. The differences in behavior come from the formulation, the complexing proteins, the excipients, and the unit-dosing conventions — which are not interchangeable between products.
Unit conversion is not straightforward
Daxxify Units and Dysport Units are not equivalent. This is stated explicitly in both prescribing information documents and is one of the most clinically important distinctions.
| Daxxify | Dysport | |
|---|---|---|
| Labeled glabellar dose | 40 Units total (5 × 8 Units) | 50 Units total (5 × 10 Units) |
| Unit basis | Proprietary assay; not interchangeable with any other product | Proprietary assay; not interchangeable with any other product |
| Approximate conversion to Botox | ~2:1 (40 U Daxxify ≈ 20 U Botox) | ~2.5:1 (50 U Dysport ≈ 20 U Botox) |
Neither product should be dose-converted at the same numerical ratio as the other. Clinicians switching between products base adjustments on clinical response, not on arithmetic conversion. Patients should not assume that "more units" means a stronger product.
Onset: Dysport is faster
Dysport's smaller toxin complex size is associated with faster diffusion from the injection site. Per the prescribing information and clinical literature, many patients begin to see softening of treated lines within 2–3 days after Dysport injection. Peak effect typically occurs at around 7–14 days.
Daxxify onset is also relatively fast. Per the manufacturer's pooled patient diary data from the SAKURA Phase 3 trials, some patients reported measurable improvement within 1–2 days. However, the FDA label does not make a specific onset claim, and real-world clinical reports suggest the full effect may take closer to 5–7 days to become visible.
In practice: Dysport has a slight but consistent onset advantage. Patients treating for an upcoming event (a wedding, a photoshoot) may prefer Dysport if timing is tight. The difference is measured in days, not weeks.
Duration: Daxxify is substantially longer
This is the headline distinction.
In the SAKURA 1 and SAKURA 2 Phase 3 trials (cited in the Daxxify prescribing information), at least 50% of patients maintained "none or mild" glabellar line severity for 24 weeks (approximately 6 months). Some patients maintained response for up to 9 months in open-label extension studies.
Dysport's labeled duration for glabellar lines is "up to four months," consistent with the prescribing information. In practice, most patients return for retreatment at 3–4 month intervals.
The duration difference is real, but it carries caveats:
- The Daxxify duration data are based on a 40 Unit dose — roughly twice the Botox-equivalent dose used in head-to-head trials of other products. Whether the duration advantage holds at lower doses is less clear.
- Duration varies by treatment area, individual metabolism, muscle mass, and injection technique. Not every patient gets 6 months.
- Longer duration means longer exposure if a patient does not like the result. This is relevant for first-time neuromodulator patients.
Diffusion and spread
Dysport is known for wider diffusion from the injection site compared to Botox or Daxxify. This is a double-edged property:
- Advantage: Wider spread can be efficient for large treatment areas like the forehead, where fewer injection points may achieve broad coverage. Some patients report a softer, more natural feel compared to more localized products.
- Disadvantage: Wider spread increases the risk of unintended muscle involvement — eyelid ptosis (drooping) from forehead treatment, or asymmetry from imprecise placement. The effect is technique-dependent; an experienced injector can mitigate this.
Daxxify tends to stay more localized at the injection site, similar to Botox. This offers more precision for small or high-stakes areas (brow shaping, lip flips, masseter treatment) but may require more injection points to cover a broad area.
FDA-approved indications
| Indication | Daxxify | Dysport |
|---|---|---|
| Glabellar lines | Yes (2022) | Yes (2009) |
| Cervical dystonia | Yes (2023) | Yes (2009) |
| Upper limb spasticity (adults) | No | Yes |
| Lower limb spasticity (pediatric) | No | Yes |
| Forehead lines (off-label for both) | Common off-label | Common off-label |
| Crow's feet (off-label for both) | Common off-label | Common off-label |
All cosmetic uses beyond glabellar lines are off-label for both products. Off-label use is legal and common in aesthetic practice, but patients should be told when a product is being used outside its FDA-cleared indication.
Dysport has a broader FDA indication base due to its 13-year head start in the U.S. market. For patients with neuromuscular conditions beyond glabellar lines, Dysport has an established regulatory track record that Daxxify has not yet built.
Cost comparison
Neither product is generic, and pricing varies significantly by geography, provider, and practice type. The following ranges reflect reported U.S. averages and should be treated as approximate.
| Daxxify | Dysport | |
|---|---|---|
| Per-unit cost | $3–$5/unit | $2–$4/unit |
| Typical glabellar session | ~40 Units → $120–$200 (product cost alone) | ~50 Units → $100–$200 (product cost alone) |
| Patient out-of-pocket per session | $350–$700 | $250–$500 |
| Sessions per year (typical) | 2 | 3–4 |
| Estimated annual cost | $700–$1,400 | $750–$2,000 |
Daxxify costs more per session but requires fewer sessions per year. For patients who maintain 6-month duration, the annual cost can be comparable to or lower than Dysport. For patients who get closer to 4 months from Daxxify, the cost advantage disappears.
Dysport offers lower per-session cost, which matters for patients budgeting appointment-by-appointment rather than annually. It also allows more granular adjustment — if a patient wants to tweak results, the 3-month retreatment cycle offers more correction opportunities.
Immunogenicity
Both products carry the class-wide boxed warning about distant spread of toxin effects and the potential for neutralizing antibody formation. This is common to all botulinum toxin products.
Daxxify is formulated without complexing proteins and without human serum albumin, which in theory reduces immunogenic exposure. However, long-term post-market antibody data for Daxxify are limited compared to Botox and Dysport, which have decades of use. A patient who develops neutralizing antibodies to one botulinum toxin product may experience reduced efficacy with others in the class, though cross-reactivity is not fully predictable.
Dysport contains human serum albumin and complexing proteins. The theoretical immunogenicity risk is somewhat higher, but clinical rates of antibody-mediated treatment failure remain low across all products when used at labeled doses and intervals.
Side effect profiles
Side effect profiles are broadly similar across botulinum toxin A products. Per the FDA labels:
Daxxify (glabellar lines, pooled Phase 3 data, N=406):
- Headache: 6%
- Eyelid ptosis: 2%
- Facial paresis: 1%
Dysport (glabellar lines, clinical trial data):
- Headache: commonly reported
- Eyelid ptosis: reported
- Injection site reactions (pain, bruising, erythema): common
Both carry the boxed warning for potential distant spread of toxin effects, including dysphagia and breathing difficulties. These events are rare at cosmetic doses but can be life-threatening.
Who is each product best for?
Daxxify may be a better fit for patients who:
- Want fewer injections per year and can tolerate higher per-session cost
- Travel frequently or have limited ability to return for 3–4 month touch-ups
- Have previously tolerated shorter-acting neuromodulators and want longer duration
- Prefer more localized effect (less diffusion)
- Have religious or personal objections to human-derived albumin in injectables
Dysport may be a better fit for patients who:
- Want the fastest possible onset
- Are treating large areas (full forehead) where wider diffusion is efficient
- Prefer lower per-session cost and more frequent adjustment opportunities
- Are first-time neuromodulator patients who want a shorter commitment window
- Have medical indications beyond glabellar lines (spasticity, cervical dystonia)
Neither product is right for patients who:
- Have known hypersensitivity to botulinum toxin or any product component
- Have an active infection at the injection site
- Are pregnant or breastfeeding (neither product has been studied in these populations)
- Have a neuromuscular disorder (myasthenia gravis, Lambert-Eaton syndrome) without specialist supervision
- Are taking aminoglycoside antibiotics or other agents that interfere with neuromuscular transmission
What to ask before choosing
Before committing to either product, ask your provider:
Which product are you most experienced injecting? Injector experience matters more than product choice for most outcomes. A provider who has performed 500 Dysport sessions will likely produce better results with Dysport than with a product they have used 20 times.
What happens if I don't like the result? With Daxxify's longer duration, an unwanted outcome lasts longer. With Dysport's shorter duration, you wait less time — but you also need more visits to maintain the look you want.
Is the price per unit or per area? Per-area pricing can obscure how much product you are actually receiving. Per-unit pricing is more transparent but requires trust that the stated unit count is accurate.
Are you using this product on-label or off-label? Both Daxxify and Dysport are FDA-approved only for glabellar lines in the cosmetic setting. Any other facial area is off-label. That is routine practice, but patients should know.
What is your protocol if something goes wrong? Eyelid ptosis, asymmetry, and unwanted spread are known risks. An experienced provider has a plan for these — often involving apraclonidine eye drops for ptosis or simply waiting for the effect to wear off.
Sources
- Daxxify (daxibotulinumtoxinA-lanm) prescribing information, FDA. accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf
- Daxxify FDA approval package, BLA 761127. accessdata.fda.gov/drugsatfda_docs/nda/2022/761127Orig1s000Approv.pdf
- Dysport (abobotulinumtoxinA) prescribing information, FDA. accessdata.fda.gov/drugsatfda_docs/label/2023/125274s125lbl.pdf
- Daxxify HCP page, Revance Therapeutics. hcp.daxxify.com
- American Society of Plastic Surgeons, 2024 Procedural Statistics. plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf
- FDA warning letter re: botulinum toxin products and boxed warning requirements. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aesthetic-essentials-limited-718707-11032025
